HOME >> BIOLOGY >> NEWS
Finding a cellular Neverland: How stem cells stay childlike

La Jolla, CA - Despite their celebrated "immortality," the capacity of embryonic stem (ES) cells for endless division has its limits. After a very extended childhood spent dividing in a culture dish, even stem cells tend to grow up and assume adult roles as workaday nerve, muscle, or blood cells, never to return to their youthful state.

How some ES cells succeed in recapturing lost cellular innocence and start anew once they begin maturing is described in a forthcoming study in Proceedings of the National Academy of Sciences, authored by a team of scientists from the Salk Institute for Biological Studies.

The team, headed by professor Juan Carlos Ispiza Belmonte, Ph.D., of the Gene Expression Laboratory and including professor Fred Gage, Ph.D., of the Laboratory of Genetics, demonstrates how a DNA-binding protein called Nanog coaxes mouse ES cells trying to differentiate into muscle cells back into an immature state. Nanog is named for the legendary Celtic land Tir nan Og where people remained forever young

"Embryonic stem cells represent enormous hope for treating otherwise incurable diseases," says Belmonte. "But before we can design therapeutic strategies or introduce these cells into patients, we must learn how to differentiate them into specific cell types and how to tame their formidable proliferating ability," he explains.

Nanog is a critical factor required for what cell biologists call "stemness," which is defined by two qualities: the ability of ES cells to divide or "self-renew" and their plasticity in assuming the identity of almost any cell type, which is also known as "pluripotency."

In a study published earlier this year, the same Belmonte and Gage lab team demonstrated that a few ES cells in a culture dish tended to lose stemness and evolve into muscle cell precursors, most likely goaded by a muscle differentiation factor known as BMP. But when those maturing cells were forced to produce Nanog, they re
'"/>

Contact: Gina Kirchweger
kirchweger@salk.edu
858-453-4100 x1340
Salk Institute
26-Jun-2006


Page: 1 2 3

Related biology news :

1. Finding protection from tumor growth in unexpected places
2. Finding the white wine difference
3. Finding an answer to Darwins Dilemma
4. Finding a cure for cancer: The holy grail of science
5. Finding the right mix: A biomaterial blend library
6. Finding paves way for better treatment of autoimmune disease
7. Finding about cellular microtubule rigidity could lead to development of new nano-materials
8. Findings by Einstein scientists reveal possible strategy against obesity, diabetes and infertility
9. Finding of a new molecular marker of resistance to chemotherapy in breast cancer
10. Finding a virus is not all bad news
11. Finding life on Mars and outer space begins by examining Earths inner space

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Finding cellular Neverland How stem cells stay childlike

(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: